Gain Therapeutics (GANX) Stock Price, News & Analysis

Company Overview

Gain Therapeutics, Inc. (NASDAQ: GANX) is a clinical-stage biopharmaceutical company focused on precision therapeutics for neurodegenerative and rare diseases. The company leverages its proprietary allosteric modulation platform, AlphaTarget, to discover and optimize small molecule modulators that bind to non-active sites on target proteins. By correcting protein folding and function, Gain aims to provide disease-modifying treatments with improved selectivity and reduced off-target effects.

Gain’s lead clinical candidate, GT-022, is being developed for Gaucher disease, a rare lysosomal storage disorder characterized by deficient enzyme activity. In addition to its clinical program, the company is advancing preclinical pipelines targeting Parkinson’s disease and other central nervous system disorders. Using structure-based design and high-throughput screening, Gain seeks to expand its pipeline across multiple indications with high unmet medical need.

Headquartered in Geneva, Switzerland, with research operations in Massachusetts, Gain Therapeutics was founded in 2015 and has since established collaborations with academic centers and industry partners to support its discovery and development efforts. The company is led by a management team with experience in biotechnology, pharmaceutical development, and protein science, guiding Gain through translational research toward clinical validation.

Key Stats

• Today's Range: $1.69 to $1.74
• 50-Day Range: $1.44 to $1.99
• 52-Week Range: $1.33 to $3.19
• Volume: 299,290 shs
• Average Volume: 301,784 shs
• Market Capitalization: $62.19 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $8.00
• Consensus Rating: Buy

Gain Therapeutics Stock Analysis - MarketRank™

Gain Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 395th out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Buy

Consensus Rating

Gain Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

Upside Potential

Gain Therapeutics has a consensus price target of $8.00, representing about 362.4% upside from its current price of $1.73.

Amount of Analyst Coverage

Gain Therapeutics has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Gain Therapeutics are expected to grow in the coming year, from ($1.00) to ($0.79) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Gain Therapeutics is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Gain Therapeutics is -2.75, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Gain Therapeutics has a P/B Ratio of 6.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.62% of the float of Gain Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gain Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gain Therapeutics has recently decreased by 13.21%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Gain Therapeutics does not currently pay a dividend.

Dividend Growth

Gain Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.62% of the float of Gain Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Gain Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Gain Therapeutics has recently decreased by 13.21%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.62

News Sentiment

Gain Therapeutics has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.84 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 6 news articles for Gain Therapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added Gain Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Gain Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 7.18% of the stock of Gain Therapeutics is held by insiders.

Percentage Held by Institutions

Only 11.97% of the stock of Gain Therapeutics is held by institutions.

GANX Stock Analysis - Frequently Asked Questions

How have GANX shares performed this year?

Gain Therapeutics' stock was trading at $2.16 at the start of the year. Since then, GANX shares have decreased by 19.9% and is now trading at $1.73.

How were Gain Therapeutics' earnings last quarter?

Gain Therapeutics, Inc. (NASDAQ:GANX) issued its quarterly earnings data on Tuesday, August, 12th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.17) by $0.02.

When did Gain Therapeutics IPO?

Gain Therapeutics (GANX) raised $40 million in an IPO on Thursday, March 18th 2021. The company issued 3,600,000 shares at a price of $10.00-$12.00 per share. BTIG and Oppenheimer & Co,. served as the underwriters for the IPO and National Securities Corp. was co-manager.

Who are Gain Therapeutics' major shareholders?

Top institutional investors of Gain Therapeutics include Geode Capital Management LLC (0.97%) and Marshall Wace LLP (0.92%). Insiders that own company stock include Khalid Islam, Jeffrey Scott Riley, Gene Mack and Matthias Alder.
View institutional ownership trends.

How do I buy shares of Gain Therapeutics?

Shares of GANX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Gain Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Gain Therapeutics investors own include PayPal (PYPL), Pfizer (PFE), SEA (SE), Taiwan Semiconductor Manufacturing (TSM), ZIM Integrated Shipping Services (ZIM), ADC Therapeutics (ADCT) and Avino Silver & Gold Mines (ASM).

Company Calendar

• Last Earnings: 8/12/2025
• Today: 9/10/2025
• Next Earnings (Estimated): 11/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GANX
• CIK: 1819411
• Web: www.gaintherapeutics.com
• Phone: 301-500-1556
• Fax: N/A
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Gain Therapeutics: $8.00
• High Price Target: $12.00
• Low Price Target: $6.00
• Potential Upside/Downside: +369.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.63)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -289.10%
• Return on Assets: -155.11%

Debt

• Debt-to-Equity Ratio: 0.09
• Current Ratio: 1.79
• Quick Ratio: 1.79

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: 6.09

Miscellaneous

• Outstanding Shares: 35,949,000
• Free Float: 33,368,000
• Market Cap: $61.29 million
• Optionable: Optionable
• Beta: 0.14